Physician profile
Ralph Digiovanni
NPI 1053428144
$6,705.88
in general payments reported to CMS, 2019-2025
26 companies · $993 in 2025
The $993 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,159 · 2020: $429 · 2021: $1,291 · 2022: $1,109 · 2023: $725 · 2024: $1,000 · 2025: $993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,718.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,063.89 | 2019-2025 | Clareon, Clareon Panoptix Pro, Dailies Total1 |
| Johnson & Johnson Vision Care, INC. | $998.32 | 2019-2025 | Acuvue |
| Sun Pharmaceutical Industries INC. | $442.34 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $340.39 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $335.43 | 2019-2023 | |
| Coopervision INC. | $322.72 | 2020-2025 | Myday Contact Lens |
| Bausch & Lomb Americas INC. | $248.42 | 2022-2025 | Infuse, Miebo, Xiidra |
| Abbvie INC. | $235.92 | 2022-2025 | |
| Oyster Point Pharma, INC. | $225.54 | 2022-2024 | Tyrvaya, Ryzumvi |
| Harrow Eye, LLC | $214.64 | 2024-2025 | Vevye |
| Aerie Pharmaceuticals, INC. | $204.70 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $201.24 | 2019-2021 | |
| Allergan, INC. | $183.20 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $170.23 | 2020-2021 | |
| Abb Con-Cise Optical Group LLC | $142.23 | 2021-2024 | Contact Lens, Spectacle Lenses |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $114.49 | 2024-2025 | Oxervate |
| Sight Sciences, INC. | $73.10 | 2022-2024 | Tearcare System |
| Amgen INC. | $41.19 | 2024 | Tepezza |
| Eyevance Pharmaceuticals LLC | $25.56 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $23.33 | 2025 | Syfovre |
| Ani Pharmaceuticals, INC. | $19.64 | 2025 | Purified Cortrophin Gel |
| Ocular Therapeutix, INC. | $18.38 | 2019 | |
| Biotissue Holdings INC. | $18.16 | 2025 | |
| Horizon Therapeutics Plc | $15.90 | 2021 | |
| Kala Pharmaceuticals, INC. | $15.28 | 2019 | |
| Shire North American Group INC | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Digiovanni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.